Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RMTI 
Rockwell Medical Inc (RMTI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/14/2025: RMTI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.6% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 38.71M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 2 | Beta 1.62 | 52 Weeks Range 0.78 - 5.15 | Updated Date 07/14/2025 |
52 Weeks Range 0.78 - 5.15 | Updated Date 07/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -0.27% | Operating Margin (TTM) -7.19% |
Management Effectiveness
Return on Assets (TTM) 0.68% | Return on Equity (TTM) -1.01% |
Valuation
Trailing PE - | Forward PE 59.17 | Enterprise Value 34248430 | Price to Sales(TTM) 0.4 |
Enterprise Value 34248430 | Price to Sales(TTM) 0.4 | ||
Enterprise Value to Revenue 0.35 | Enterprise Value to EBITDA 11.38 | Shares Outstanding 34257900 | Shares Floating 27783679 |
Shares Outstanding 34257900 | Shares Floating 27783679 | ||
Percent Insiders 12.66 | Percent Institutions 20.56 |
Upturn AI SWOT
Rockwell Medical Inc
Company Overview
History and Background
Rockwell Medical Inc., founded in 1995, develops, manufactures, and commercializes solutions for hemodialysis. It initially focused on dialysis concentrates and has expanded to include dialysis drug therapies.
Core Business Areas
- Dialysis Solutions: Production and distribution of hemodialysis concentrates (acid and bicarbonate) and other ancillary products used in dialysis treatments.
- Dialysis Drug Therapies: Development and commercialization of drug therapies focused on treating iron deficiency and related conditions in dialysis patients.
Leadership and Structure
Rockwell Medical has a Board of Directors and an executive leadership team headed by its Chief Executive Officer. The organizational structure includes departments for research and development, manufacturing, sales and marketing, and finance.
Top Products and Market Share
Key Offerings
- Dialysate Concentrates: Rockwell Medical's core product line, providing concentrated solutions used in dialysis machines. Market share data is not readily available. Competitors include Baxter International and Fresenius Medical Care.
- Iron Deficiency Drugs: Currently not yet approved by the FDA so no Market Share and revenue data available.
Market Dynamics
Industry Overview
The hemodialysis market is characterized by increasing prevalence of chronic kidney disease (CKD) and a growing aging population. It's dominated by a few large players, but Rockwell Medical is a key player providing dialysate concentrates.
Positioning
Rockwell Medical aims to be a specialized provider of dialysis solutions and drug therapies. Its competitive advantage lies in its expertise in dialysis concentrates and focus on addressing unmet needs in dialysis patient care.
Total Addressable Market (TAM)
The global dialysis market is estimated to be in the tens of billions of dollars annually. Rockwell is positioned to compete in the dialysate concentrate and potentially the iron deficiency drug therapy segments.
Upturn SWOT Analysis
Strengths
- Established presence in the dialysis concentrate market
- Focus on specialized dialysis solutions and drug therapies
- Strong relationships with dialysis clinics and providers
- Intellectual property portfolio
Weaknesses
- Limited product portfolio compared to larger competitors
- Reliance on dialysis concentrates as a primary revenue source
- Dependence on regulatory approvals for new drug therapies
Opportunities
- Expanding into new geographic markets
- Developing innovative drug therapies for dialysis patients
- Partnering with larger dialysis providers
- Capitalizing on the growing prevalence of CKD
Threats
- Intense competition from larger, established players
- Pricing pressures from dialysis providers and payers
- Regulatory hurdles for drug approvals
- Changes in dialysis treatment guidelines
Competitors and Market Share
Key Competitors
- BAX
- FMS
- DVA
Competitive Landscape
Rockwell Medical faces significant competition from larger, well-established companies. It differentiates itself through its focus on dialysis solutions and drug therapies. Its future success depends on gaining market share through innovative products and strategic partnerships.
Growth Trajectory and Initiatives
Historical Growth: Requires access to live financial data sources.
Future Projections: Requires access to analyst estimates.
Recent Initiatives: Requires access to company announcements.
Summary
Rockwell Medical is a specialized player in the dialysis market, primarily focusing on concentrates. They face stiff competition from larger companies and depend on their smaller but focused expertise. Any successful growth relies on successfully developing and commercializing new therapies. Regulatory challenges and competition will remain threats.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions are constantly evolving, and actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rockwell Medical Inc
Exchange NASDAQ | Headquaters Wixom, MI, United States | ||
IPO Launch date 1998-01-27 | President, CEO & Director Dr. Mark Strobeck Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 244 | Website https://www.rockwellmed.com |
Full time employees 244 | Website https://www.rockwellmed.com | ||
Rockwell Medical, Inc., together with its subsidiaries, develops, manufactures, commercializes, and distributes various hemodialysis products for dialysis providers worldwide. The company offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, centrisol and renasol hemodialysis concentrates, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers. Its hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics, including dialysis concentrates, dialysis kits, and other ancillary products used in the dialysis process. Rockwell Medical, Inc. was formerly known as Rockwell Medical Technologies, Inc. and changed its name to Rockwell Medical, Inc. in June 2012. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.